72 results about "Nervous disease" patented technology

The invention discloses a nerve disease detection and analysis method and system, and the method comprises the steps: obtaining a bracelet collection signal, a sphygmomanometer collection signal, a movement behavior image and behavior test data, and extracting tremor intensity features, gait symmetry features and autonomic nerve rhythm features through multi-band decomposition of the bracelet collection signal; analyzing the motion behavior image and the standardized motion test to obtain a motion function score; carrying out heart rate variability analysis to identify a neural function abnormality mode; constructing a neural function state map and calculating a feature weight; predicting a disease progress trend in combination with historical monitoring data; and dynamically adjusting a prediction result through subsequent feedback correction information. Through a mode of combining short-time intensive monitoring and long-term intermittent acquisition, long-term trend prediction and dynamic correction based on initial data are realized, and the reliability and practicability of nerve disease risk assessment in a home scene are remarkably improved.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.

The invention discloses a deep brain targeted stimulation method based on a time-frequency interference technology, and relates to the technical field of nerve regulation, and an application system comprises a plurality of pairs of stimulation electrode modules, a data acquisition module, a data preprocessing module, a time-frequency interference stimulation signal generation module, a central control module and a data storage module. According to the method, a multi-azimuth surrounding layout of multiple pairs of stimulation electrodes is combined with a time-frequency interference technology, so that a high-frequency electric field forms constructive interference in a deep brain target area, and meanwhile, a frequency difference is dynamically adjusted based on different organism state requirements; and a closed-loop control system of data acquisition, preprocessing, state evaluation, parameter adjustment and stimulation application is constructed. The problems that a traditional deep brain stimulation technology is low in targeting precision, poor in state guiding efficiency and insufficient in stimulation system stability are solved, the energy focusing degree is improved to 90% or above, the sleep induction time is shortened to 20-30 minutes, and the method can be widely applied to nerve disease treatment and physiological state improvement.

Compositions comprising an isolated population of nanovesicles from a plant, mushroom or algae are provided. Methods of treating muscle and bone diseases, treating neurological diseases, treating age-related disease, inducing muscle differentiation, inducing neuronal differentiation, treating malnutrition, reducing inflammation and reducing oxidative stress by administering a composition comprising an isolated population of nanovesicles from a plant, mushroom or algae are also provided. Methods of delivering a compound to a cell comprising loading the compound into nanovesicles from a plant, mushroom or algae and contacting the cell with the loaded nanovesicles are also provided.

Particles are provided that include a liposome having a negatively charged outer surface and a lipid-drug conjugate, a first layer of cationic polymer such as poly-L-arginine (PLR), that is non-covalently associated with the negatively charged outer surface of the liposome, and a second layer having a mixture of an anionic polymer and polyethylene glycol modified anionic polymer that is non-covalently associated with the first layer. The particles can be formulated as pharmaceutical compositions that are useful in methods that target neurological disorders such as brain tumors and other neurological diseases, and that can deliver and / or transport therapeutic drugs across the blood brain barrier.

The present invention relates to a method for selecting highly potent stem cells for the treatment of neurological disease using TIMP-1, MCP-1, GROα, and IL-6, and a pharmaceutical composition for the prevention or treatment of neurological disease. According to the present invention, a specific combination of markers including TIMP-1, MCP-1, GROα, and IL-6 can be used as a biomarker for selecting stem cells with superior therapeutic (ameliorating) potential in the treatment of neurological disease. Moreover, the application of stem cells exhibiting increased expression or activity of TIMP-1, MCP-1, GROα, and IL-6 factors or the use of substances that regulate (particularly upregulate) these factors in stem cells has a remarkable therapeutic effect on neurological disease due to having high efficacy (potency) and efficiency. Furthermore, the present invention presents the higher therapeutic potential of allogeneic stem cell transplantation.

Provided herein are SOD1 RNAi agents and compositions comprising a SOD1 RNAi agent. Also provided herein are methods of using the SOD1 RNAi agents or compositions comprising a SOD1 RNAi agent in reducing SOD1 expression and / or treating SOD1-mediated neurological disease.

An preventive or therapeutic agent for optic nerve diseases comprises an effective amount of an artificial synapse connector or a nucleic acid encoding the artificial synapse connector.

To provide a preventive or improving agent for neurological disorders caused by nerve damage resulting in reduced nerve function.SOLUTION: The preventive or improving agent contains a combination of quinoa or extract thereof and gluconodeltalactone.SELECTED DRAWING: None

The application of CpG oligonucleotides in drugs for diabetic cardiac autonomic neuropathy: Experiments have confirmed that CpG oligonucleotide 1826 can reduce the activation of satellite glial cells in the stellate ganglion and the expression of inflammatory cytokines, inhibit the expression of purine 2Y12 receptors, and reduce lipid peroxidation damage to alleviate ferroptosis in stellate ganglion neurons, thereby improving cardiac autonomic nerve function. Examples of CpG oligonucleotide 1826 demonstrate that CPG-ODN with anti-inflammatory effects or with anti-damage protective effects on the sympathetic nervous system has preventive and therapeutic effects in diabetic cardiac autonomic neuropathy and sympathetic nerve injury-related diseases.

The invention relates to the technical field of nerve cell differentiation, and discloses a culture medium for promoting neural differentiation of SH-SY5Y cells. The culture medium disclosed by the invention is prepared from the following components: tazarotene (tazarotene) and a basic culture medium. The culture medium can promote SH-SY5Y cells to present neuron-like differentiation within 5 days, significantly improves the length of neurite and the expression level of neuron markers, and is low in cytotoxicity. The invention provides an efficient, safe and standardized new tool for neural disease in-vitro model construction, drug screening and mechanism research.

kinase inhibitor. 20 26 20 54 07 08 J ul 2 02 6 A B S T R A C T 2 0 2 6 2 0 5 4 0 7 0 8 J u l 2 0 2 6 k i n a s e i n h i b i t o r .

This disclosure relates to reagents such as antisense oligonucleotides that bind to nucleic acids encoding cryptic exons, thereby inhibiting or preventing ELAVL3 cryptic splicing, and to their use in the treatment or prevention of TDP-43-related neurodegenerative or neurological diseases or conditions associated therewith. In some embodiments, the antisense oligonucleotide is a nucleobase polymer capable of reducing the level or expression of intracellular ELAVL3 cryptic exon RNA and increasing or restoring the expression of functional ELAVL3 protein without substantially incorporating the cryptic exon RNA peptide sequence.

The invention belongs to the technical field of biological medicines, and relates to phenyl naphthalene derivatives and application thereof in preparation of medicines for preventing and treating tumors or medicines for neuroprotection. The compound is a compound shown in a formula I or a formula II or a pharmaceutically acceptable salt thereof. In the formula I, A is not present or is carbonyl, A'is carbonyl, sulfuryl, oximido and imino, R1 is amino, nitryl, acylamino, sulfonamide, aryl methoxy, aryl ethyoxyl, fluorine atom, trifluoromethyl, ureido, amidoxime, amidino and N-methyl sulfonamide, and R2 is hydrogen atom, methoxy, amino, nitryl, acylamino, amidoxime, amidino or fluorine atom; r2 and H2N-A'are located at the adjacent position of a benzene ring, R2 or H2N-A 'is located at the para-position of phenyl, and X1 and X2 are independently selected from CH or N. The phenyl naphthalene derivative provided by the invention has relatively high NQO2 inhibitory activity, and can be used as a chemical drug for tumor treatment and a neuroprotective agent for neurological diseases.

Disclosed in the present invention is a pharmaceutical composition, comprising anisodine or a salt thereof and 2-borneol or a related substance thereof. The pharmaceutical composition provided in the present invention exhibits synergistic effects in the treatment of cardiovascular and cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, and can effectively improve outcomes of patients with cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, thereby enhancing the quality of life of the patients.

The invention discloses an application of lignan B in preparation of a medicine for preventing and / or treating neurodegenerative diseases or neurological diseases. In-vitro cell experiments and animal model researches find that the Licarin B can significantly reduce the expression level of ABAD or inhibit the enzymatic activity of ABAD, so that the nerve cell activity is improved, neuroinflammation is reduced, the epileptic seizure frequency is reduced, and the cognitive function is improved. The invention provides the new application of the Licarin B in preparing the medicine for preventing or treating the neurodegenerative diseases and the epilepsy for the first time, and a new way and means are developed for preventing and treating the neurodegenerative diseases and the epilepsy.

The application provides a kind of nanorobot and its control method, carry the modified reverse sodium-potassium pump, can long time, continuously use the ion concentration change of organism itself to realize the regulation of nerve activity, can be widely applied to the intervention of a variety of nervous system excitation / inhibition imbalance related neurological diseases;Through the recognition of specific neuron's axon hillock initial segment by the potential receptor and field driving element, more accurate targeted regulation can be achieved;Through the characteristics of precise control of movement of ultrasonic wave of ultrasonic wave driving element, combined with imaging equipment, brain region targeted movement of nanorobot is realized, the nanorobot and its control method provided by the application improve the existing nanorobot, through the modified functional element, to realize the target brain region targeted guidance, neuron recognition and long-term regulation.

The present invention relates to kits and diagnostic methods for multiple biomarkers or their isoforms as well as to methods for determining and selecting treatment methods based on the results obtained from said kits and diagnostic methods. In particular, the invention relates to improved lateral flow (LFA) strips, cassettes containing the LFA assay strips as well as to kits containing the strips and cassettes. The invention also relates to methods for subclassing patients into various subtypes based on the simultaneous detection of three or more different biomarkers or isoforms of biomarkers.

Provided herein are ATXN2 RNAi agents and compositions comprising an ATXN2 RNAi agent. Also provided herein are methods of using the ATXN2 RNAi agents or compositions comprising an ATXN2 RNAi agent for reducing ATXN2 expression, and / or treating ATXN2-associated neurological disease in a subject.

The invention relates to a median nerve volume ultrasonic diagnosis device based on artificial intelligence, which comprises an automatic scanning mobile device, a coupling medium container, a handheld portable ultrasonic control device and a three-dimensional ultrasonic probe, is convenient to carry, and is not limited by use scenes. A median nerve disease prediction model and a median nerve disease diagnosis system are established, detection and analysis of median nerves can be automatically completed based on the established model and the artificial intelligence diagnosis system, a test result is obtained, the whole test process is not affected by skills of an operator, and the stability is high.

The present invention relates to a composition for improving memory, improving cognition, preventing or treating cerebral neurological disease, comprising porcine brain enzyme hydrolysate. The composition can exhibit neuroprotective activity, brain-derived neurotrophic factor (BDNF) production activity, acetylcholinesterase inhibitory activity and reactive oxygen species (ROS) inhibitory activity.

The invention belongs to the technical field of cell culture, and particularly relates to a culture method and application of human astrocytes. According to the culture solution provided by the invention, DMEM (Dulbecco Modified Eagle Medium) and MCDB 131 are mixed according to a specific ratio to form a basic culture medium, and functional additives of HEPES, Glutamax, N2, G-5, B-27, hEGF (Human Epidermal Growth Factor) and the like with accurate concentration and fetal calf serum with proper concentration are matched. The culture solution can effectively improve the vitality and proliferation efficiency of SVGP12 cells, guarantees the growth stability and morphological consistency of the cells, can provide a high-quality and reliable cell source for the application of human astrocytes in the fields of neurobiology research, neurological disease mechanism exploration, drug screening and the like, and has important practical value.

The invention discloses a dietary therapy formula for repairing damaged cells and promoting cranial nerve development and a preparation method, and the dietary therapy formula comprises the following components in parts by weight: 1-2 parts of bone collagen peptide, 1-2 parts of taurine, 1-2 parts of bovine bone marrow powder, 2-4 parts of inulin, 2-4 parts of acerola cherry fruit powder, 3-4 parts of guarana extract and 4-6 parts of N-acetylneuraminic acid. 4-5 parts of vitamin B6, 2-4 parts of vitamin B1 and 2-4 parts of vitamin B2; the traditional Chinese medicine composition is capable of repairing damaged cells and promoting cranial nerve development, and has remarkable effects of inhibiting the onset of neurological diseases, promoting the repair of nerve cells and promoting nerve development.

The invention relates to an engineered extracellular vesicle for treating central nervous system diseases as well as a preparation method and application of the engineered extracellular vesicle. Specifically, the invention provides the expression cassette which has a structure shown as a formula I, a carrier containing the expression cassette, a host cell and extracellular vesicles generated by utilizing the cell. The engineered extracellular vesicles provided by the invention are rich in therapeutic proteins and have excellent blood brain barrier permeability.

The present technology relates to a genus of compounds comprising a subunit of arimoclomol covalently linked to a subunit of miglustat. The present technology further relates to compositions comprising said compounds and method of treating neurological diseases and disorders using said compounds.

The invention discloses a dietary therapy formula for repairing damaged cells and promoting cranial nerve development and a preparation method, and the dietary therapy formula comprises the following components in parts by weight: 1-2 parts of bone collagen peptide, 1-2 parts of taurine, 1-2 parts of bovine bone marrow powder, 2-4 parts of inulin, 2-4 parts of acerola cherry fruit powder, 3-4 parts of guarana extract and 4-6 parts of N-acetylneuraminic acid. 4-5 parts of vitamin B6, 2-4 parts of vitamin B1 and 2-4 parts of vitamin B2; the traditional Chinese medicine composition is capable of repairing damaged cells and promoting cranial nerve development, and has remarkable effects of inhibiting the onset of neurological diseases, promoting the repair of nerve cells and promoting nerve development.

Disclosed are a composition and method for inhibiting tau protein accumulation, aggregation, or tangle, the composition containing neurons or glia having Nurr1 and / or Foxa2 genes introduced thereinto, wherein the composition and method can be utilized in the prevention or treatment of a cerebral nervous disease caused by tau protein accumulation, aggregation, or tangle formation.

The invention relates to an eye disease and nerve disease integrated diagnosis and treatment system based on visual signal perception, and belongs to the technical field of visual function detection and diagnosis and treatment assistance. The method comprises the following steps: dynamically generating a black and white checkerboard stimulation signal through a visual stimulation generation unit, and triggering an eye and a nervous system to generate an original evoked potential signal; the signal acquisition and transmission unit acquires and sends the signal through an electrode plate and a wireless transmission module; the signal processing and judging unit is used for carrying out superposition processing on the signals, extracting effective waveforms and automatically executing spatial frequency threshold search to determine a minimum checkerboard; and the diagnosis and treatment scheme output unit generates a stimulation program based on the minimum checkerboard and dynamically generates a personalized diagnosis and treatment report. The full-process automation from stimulation generation, signal processing to scheme output is realized, the accuracy of threshold judgment and the personalization of the stimulation scheme are improved, and efficient and reliable technical support is provided for auxiliary diagnosis and curative effect evaluation of eye diseases and nerve diseases.

Provided herein are compounds, methods, and compositions for determining whether a patient has a neurological disease or condition, comprising detecting the presence or cumulative mass thereof of a detectable target protein in a tissue or sample of the patient, such as the presence or cumulative mass thereof of amyloid beta protein or phosphorylated tau protein. The detection may comprise contacting the target protein with a compound described herein.

The utility model discloses an improved beryllium needle which comprises a beryllium needle handle, a beryllium needle body is integrally and fixedly installed below the beryllium needle handle, a tip part is arranged at the lower end of the beryllium needle body, and blades are arranged on the two sides of the beryllium needle body. The length size of the beryllium needle handle is 8cm, the width size of the beryllium needle handle is 1cm, and the thickness size of the beryllium needle handle is 4mm; the length of the beryllium needle body is 8 cm, the width of the beryllium needle body is 4 mm, and the thickness of the beryllium needle body is 2 mm. According to the improved beryllium needle, the needle body of the beryllium needle is thinned, the blades on the two sides of the beryllium needle become blunt, side injuries are avoided, the tip is sharp and slightly expanded, lesion positions are better cut, various orthopedics and traumatology diseases, peripheral nerve diseases and the like can be safely treated, and the improved beryllium needle has the advantages of being good in curative effect, small in wound, small in damage, free of pain and the like. And the beryllium needle handle and the beryllium needle body form a certain included angle, so that the operation is better.